Gilead Sciences, Inc. (GILD)

NASDAQHealthcare

$127.6
+$3.43 (+2.8%)

January 21, 2026 at 19:18 UTC

Interactive Chart
GILD
1H
3H
6H
12H
1D
1W
1M
3M
6M
12M (YTD)
2Y
5Y
All
About Gilead Sciences, Inc.

Name

Gilead Sciences, Inc.

CEO

Daniel O'Day

Industry

Healthcare

Year Founded

1987

Employees

17,600

Gilead Sciences, Inc. is a biopharmaceutical company focused on antiviral and immunology therapies that are used by health systems around the world. The portfolio spans treatments for infectious diseases and serious chronic conditions, with programs that move from discovery to access through a single, repeatable pathway. Research groups work with clinical partners to translate science into medicines that can be delivered at scale, while medical affairs teams support appropriate use in real settings. Manufacturing and quality systems favor reliability over showy launches, so supply stays steady as demand shifts between regions. The company operates across the Americas, Europe, and Asia with a consistent emphasis on safety, evidence, and responsible distribution. In coverage of large-cap biotech, Gilead Sciences, Inc. stock (GILD) often marks investor interest in therapeutic franchises that combine established use with ongoing research.

Analyst Ratings
Consensus Recommendation
Analyst consensus: 13 Buy, 7 Hold, 1 Sell
Buy13
Hold7
Sell1
Fundamentals & Financials
Revenue (TTM)
$29B
Net Income (TTM)
$8.1B
EPS (TTM)
$6.52
ROA (TTM)
13.86%
Current Ratio
1.45
Dividend Yield
0.1%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement (Quarterly)
ItemQ3 2025
Revenue$7,769M
Cost of Sales$1,569M
Gross Profit$6,200M
Operating Income$3,327M
Net Income$3,052M
EPS$2.46
Technical Indicators

Gilead Sciences, Inc.'s Technical Indicators Summary

GILD is showing a bullish technical profile as its current price comfortably exceeds key moving averages across short, medium, and long-term horizons, indicating an established upward trend. Momentum indicators such as the MACD and Momentum (10) reinforce this positive bias, while the RSI and CCI remain neutral, suggesting room for further movement without overextension. Although the ADX points to moderate trend strength, the steady on-balance volume supports sustained buying interest. Volatility is relatively stable, with the ATR reflecting modest price fluctuation. Overall, the technical signals align to depict a constructive environment for GILD, highlighted by strong moving average support and positive momentum. The technical takeaway: GILD maintains a firm bullish stance with healthy momentum and volume backing.

Buy
13 signals
Neutral
7 signals
Sell
1 signal
Overall: Bullish62% Bullish signals
IndicatorValue
RSI (14)
54.82
Stochastic %K (14, 3, 3)
73.90
CCI (20)
52.74
WPR (14)
-4.29
Momentum (10)
3.31
MFI
42.92
MACD Level (12, 26)
0.05
Bollinger Bands
$119.05 - $126.78
ATR (14)
$3.20 (2.56%)
ADX (14)
13.11
OBV
218,774,800
Simple Moving Averages
$114.41 - $123.13(5 indicators)
Exponential Moving Averages
$115.20 - $122.69(5 indicators)
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.

Today's Snapshot

The day started with a slight downside bias as GILD opened -0.330% lower at 123.73 versus 124.14. Early options trading in GILD is strongly risk-off, as PCR spikes to 1.71. GILD opened slightly lower amid risk-off options and mixed headlines, with no clear single driver.

Price Change

from $124.14 close

+$2.26

Trading Volume

Below avg (7.0M)

971.8K

vs S&P 500 Today

Outperforming Market

+1.40%

52-Week Position

Near highs

93.8%

Updated: January 21, 2026 at 15:34 UTC

Quote Summary
OpenPrevious Close
$123.73$124.14
Day Range52 Week Range
$122.68 - $127.96$91.84 - $128.7
VolumeAvg. Volume
2.7M6.8M
Market CapP/E Ratio
$158.6B19.8